Johns Hopkins Researchers Identify a Bone Hormone That May Help Reduce Chronic Back Pain

A study published in the journal Bone Research found that parathyroid hormone, a naturally occurring bone hormone, significantly reduced abnormal pain-sensing nerve growth in damaged spinal tissue in animal models. Here is what the research found, what it means for spinal health science, and how it fits into the broader picture of non-surgical back pain care.

What the Johns Hopkins PTH Study Found and Why It Matters

Back pain is among the most common and costly health conditions worldwide, affecting hundreds of millions of people and representing one of the leading reasons patients seek medical care. Despite decades of research, the mechanisms behind chronic spinal pain remain incompletely understood, and many patients continue to cycle through treatments that provide only partial or temporary relief. This is part of why new research directions in spinal pain biology receive serious attention from clinicians and scientists.

A study published in Bone Research, Volume 14, 2026, from Johns Hopkins University School of Medicine's Department of Orthopedic Surgery and Center for Musculoskeletal Research identified a connection between a bone hormone called parathyroid hormone (PTH) and the proliferation of pain-sensing nerve fibers in deteriorating vertebral endplate tissue. Under the direction of Dr. Janet L. Crane, the team used three separate mouse models, each chosen to replicate a different common cause of spinal degeneration.

The core finding involved a specific mechanism: PTH stimulates bone-building cells, known as osteoblasts, to produce a protein called Slit3. This protein has been found to repel pain-sensing nerve fibers, meaning it can inhibit those nerves from growing into areas of damaged spinal tissue where their presence generates pain signals. In the study, mice that received daily PTH injections over periods ranging from two weeks to two months showed denser and more stable vertebral endplates and measurably reduced pain sensitivity when responding to pressure and heat stimuli.

This is basic-science research at an early stage. The findings come from animal studies, and human clinical trials would need to be conducted before any PTH-based treatment for back pain could be assessed for use in patients. Nevertheless, the study represents a meaningful addition to the scientific understanding of how bone biology and pain pathways interact in the spine.

Understanding Vertebral Endplates and Their Role in Back Pain

The vertebral endplate is a structure that most people outside the clinical world have never heard of, but it plays a central role in how spinal discs receive nutrients and how pain signals can develop. Each spinal disc sits between two vertebrae and relies on the endplates above and below it to exchange nutrients and waste products. When endplates degenerate, which can happen as a result of aging, repetitive loading, injury, or genetic predisposition, they become thinner and less functional.

As endplates deteriorate, they can become sites of abnormal nerve fiber growth. Healthy endplates have limited blood supply and nerve supply under normal circumstances. When they degenerate, the barriers that normally restrict nerve growth break down, and pain-sensing nerves can grow into the endplate tissue. These nerves then generate pain signals in response to mechanical pressure that would not cause discomfort in a healthy spine.

The PTH research from Johns Hopkins specifically focused on whether the hormone could reverse or prevent this abnormal nerve ingrowth by reinforcing the structural integrity of the endplate. The results showed that PTH treatment produced endplates that were measurably denser and structurally more stable, and that the density of abnormal nerve fibers in the treated tissue was significantly reduced compared to untreated controls. This dual effect, structural strengthening and nerve fiber reduction, makes PTH a scientifically interesting candidate for further investigation.

For patients managing chronic back pain, this research adds to a growing body of science exploring non-surgical mechanisms for addressing one of its recognized root causes. That does not mean the treatment is available or appropriate today. It means the science is moving in productive directions, and staying informed about new research helps patients and their care providers make better decisions together. This information is educational and not a substitute for a professional evaluation.

How This Research Fits Into the Broader Landscape of Non-Surgical Spinal Care

The 2026 landscape for non-surgical back pain treatment research is more active than it has been in years. Alongside the PTH endplate research from Johns Hopkins, separate work published in 2026 has explored multifidus muscle stimulation as a minimally invasive approach to restoring spinal stability, and clinical trial programs at institutions including UCSF are investigating how various non-pharmacological interventions perform for chronic low back pain populations.

One of the consistent themes across current research is the recognition that chronic back pain is rarely a single-mechanism problem. It involves structural factors, neurological factors, lifestyle factors, and in many cases psychological components that interact with each other. Research like the Johns Hopkins PTH study is valuable precisely because it focuses on a specific structural mechanism rather than attempting to address everything at once. Isolating mechanisms is how science generates actionable understanding.

For patients in the Las Vegas area managing chronic back pain, the practical takeaway from this research is that the science supporting non-surgical care continues to advance. Treatments that were not available five years ago are now part of standard conservative care, and treatments being studied today may be part of the clinical toolkit within the next decade. Working with a spine care specialist who stays current with this research is one of the best ways to ensure that your care plan reflects what the evidence actually supports.

At Las Vegas Spine and Disc, our team focuses on conservative, non-surgical spinal care grounded in current evidence. If you are managing persistent back pain or want to understand your options before considering more invasive approaches, we invite you to schedule a consultation. This article is for informational purposes only and is not a substitute for professional medical advice or examination.

6 Things to Know About the Parathyroid Hormone Back Pain Research

This study is generating real scientific interest, but it is easy to misunderstand what the findings mean at this stage. Here are the six most important things to know before drawing conclusions.

1. It is an animal study, not a human trial: The research was conducted in mouse models. No human clinical trials of PTH for back pain via the endplate mechanism described in this study have been completed. Do not interpret this as evidence of a currently available treatment.
2. PTH is already FDA-approved for osteoporosis treatment: Parathyroid hormone in synthetic forms, including teriparatide, is already approved by the FDA for treating osteoporosis in certain patients. The back pain application is a new research direction that would require separate clinical development and regulatory review.
3. The mechanism targets endplate nerve ingrowth specifically: The PTH effect in this study operates through the Slit3 protein, which inhibits pain-sensing nerves from growing into deteriorating vertebral endplates. This is a specific structural mechanism, not a broad pain-suppression effect.
4. Vertebral endplate degeneration is a recognized source of back pain: Abnormal nerve growth in degenerated endplates has been documented in human spinal tissue studies and is considered a genuine pain generator in a subset of chronic back pain cases.
5. The research was published in a Nature-affiliated peer-reviewed journal: Bone Research is a Nature-affiliated peer-reviewed journal focused on bone biology and related fields. Its peer review process provides external scientific validation for the methodology and findings reported.
6. Multiple non-surgical approaches are being investigated simultaneously in 2026: PTH endplate research is one of several active research directions alongside multifidus stimulation, enhanced acupuncture protocols, and various exercise-based interventions being studied in clinical trials at major research institutions.

← More from the Las Vegas Spine & Disc blog